Drugs intended for pain relief, prescribed nationwide in Canada, face recall due to possible life-threatening hazards
Article Update:
The nationwide recall of prescription nerve damage medication, JAMP-Pregabalin, has sent ripples across the healthcare community. The concern surrounds potential mislabeling, where some bottles marked as containing 50mg capsules may actually hold 150mg ones - a potential deadly mistake for patients.
Health Canada's warning states that overdosing on Pregabalin, used to treat nerve-related pain and fibromyalgia, could lead to life-threatening consequences. The agency urges vigilance, citing symptoms such as mood swings, sleepiness, confusion, agitation, and seizures associated with overdose.
The recall primarily impacts JAMP-Pregabalin 50mg capsules, specifically those with the Drug Identification Number 02435985, lot number 2305012747, and an expiry date of August 2026. The affected capsules are easily identifiable by the "PG" and "50" or "PG" and "150" in black ink on white capsules.
To ensure safety, Health Canada advises patients to double-check their pills. If there are any 150mg capsules or uncertainty, promptly return the affected bottles to pharmacies for verification and, if necessary, replacement. Abruptly halting the use of Pregabalin may lead to withdrawal symptoms like nausea, diarrhea, and convulsions, thus seeking medical advice before discontinuing is crucial.
Health Canada is actively monitoring the investigation into this issue and the company's corrective actions to prevent a recurrence. Patients are encouraged to report any side effects or complaints to either JAMP Pharma (1-866-399-9091, ext. 501) or Health Canada for their records.
It's crucial for pharmacists to verify bottles before dispensing JAMP-Pregabalin, as the recall is ongoing nationwide. Keep vigilant and let's work together to ensure patient safety.
- The ongoing nationwide recall of JAMP-Pregabalin, a prescription medication, has been escalating concerns within the Canadian healthcare community, particularly about potential mislabeling.
- The affected medication, used to treat various health conditions such as nerve-related pain and fibromyalgia, is JAMP-Pregabalin 50mg capsules, specifically those with the Drug Identification Number 02435985.
- Notably, the recall involves bottles that may contain 150mg capsules instead of 50mg, which could pose a fatal risk for consumers.
- Overdosing on Pregabalin can result in dangerous health consequences, including symptoms like sleepiness, mood swings, confusion, agitation, and seizures.
- To mitigate risks, Health Canada advises patients to check their pills carefully and return any affected bottles to pharmacies for verification, replacement, or recycling.
- Medical professionals are also being encouraged to report any side effects or complaints related to Pregabalin to either JAMP Pharma or Health Canada.
- It's essential for pharmacists to verify each bottle of JAMP-Pregabalin before dispensing it, as inquiries and reports continue regarding this healthcare concern in Toronto, Canada, and beyond.
